Blue Horseshoe Stocks: Z Follow-Up & More

Zillow Group, Inc. Z

First thing’s first- we wanted to update our readers once again on the Zillow calls we made on Tuesday morning. We designated the Z Weekly $48-49 Calls as our targets and after a good first day, the stock continued its upward climb during yesterday’s session.

That move alloted for even further increases on our observed range of contracts, and pushed our two-day observed swings well into multi-bag territory:

$48 Calls – Range: 1.30-3.55 – Max Gain: 173%
$48.50 Calls – Range: 1.10-2.60 – Max Gain: 136%
$49 Calls – Range: .80-2.60 – Max Gain: 225%

Fresh Ideas:
YELP Weekly $43-44.50 Calls
ROKU Weekly $52-53.50 Calls

Healthmed Services, Inc HEME

It isn’t often these days that we target a subpenny OTC stock. Our long-time followers know that those were our primary focus when we started out exactly 7 years ago this past Tuesday. We did very well in that capacity for many years, despite having recently shifted focus more to fast-paced options trading.

Of any of the sectors we ever covered in the OTC space, cannabis has certainly been the most exciting, and continues to be one of our primary interests on the stock side of things to this day.

That’s why we just want to put HEME on our readers radars. Despite being listed as defunct on OTC Markets, the company recently revealed its intentions to get things back on track and enter the marijuana space.

According to its updated website, HEME is presently acquiring, leasing and licensing growers for the cultivation, production and distribution of cannabis and cannabis-related products in southern California. The project site has state Highway access, water and local transportation are convenient and accessible, and the City government has designated the project site – legal planting zoning.

We are going to keep tabs on the company’s progress toward not only developing in this new direction, but also coming current on its reporting.

Extended Watchlist:

Incoming search terms:

  • spacedjz

Blue Horseshoe Stocks: BCLI Recap & More

BrainStorm Cell Therapeutics, Inc. BCLI

2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.

The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.

Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.

RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX

We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.

RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.

saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .

Extended Watchlist:

Blue Horseshoe Stocks: Final Report of 2014

Good Morning Traders! Here it is- the final report of 2014! We had an amazing year, with huge gainers popping out of the woodwork left, right, and center! We want to take this opportunity to thank all of our readers for being a part of our community, wish you all a Happy New Year while reminding everyone that the best is yet to come… Each year our resolution remains the same: To make the upcoming year our best one ever! We’ve succeeded time and time again, and have no reason to believe that 2015 will be any different so be sure to stay with us! Cheers!

NeuroDerm Ltd. NDRM
NDRM exceeded all expectations yesterday after we caught it on an early morning news scan; it spent the entire day in full-on breakout mode setting records in both price and volume, trading almost 27X the norm over the six week period since the stock’s IPO.

Positive response to yesterday’s early morning press statement hurtled NDRM from an early low of 8.16 all the way up to 19.07 just prior to the close, making gains of up to 134% possible.

We’ll still be standing at the ready for an eventual course correction and chance for a dip-and-rip maneuver, but any way you slice it, NDRM is getting marked down as a huge winner. It’s a great way to close out what has, on the whole, been an absolutely stellar year.

NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease (Tue 7:00AM EST)

Precious Metals on Watch: Gold, Silver

GDX and SLV have each been maintaining higher highs and higher lows since reaching a bottom in November. As we head into the New Year, we’re going to devote a good amount of focus to gold and silver, and tracking these indices and their options chains is going to be a good way to do that.

In particular, we’re going to be monitoring a few specific sets of contracts for each play:

  SLV – March $15-15.50 Calls

GDX – March $17.50-$18 Calls

As you can see from the side-by-side chart we drew up below, GDX and SLV are looking similarly ripe. We’ve got SLV breaking the 50-Line on the RSI, and GDX following closely behind in that regard, we’re seeing testing of the 50DMA’s on both charts, and each of the MACD’s are giving the indication of bullish crosses.

Side Note:
We’re also going to radar HMCP, a sub-penny momentum play that has had an interesting past few sessions.

Extended Watchlist: